INPPL1 and early-onset autosomal dominant Alzheimer disease: The compound can now be considered a candidate for in vivo efficacy studies to evaluate the potential of SHIP2 inhibitors as therapeutics for Alzheimer’s disease, with the caveat that other 5′-inositol phosphatases may also be affected and SHIP1 was recently shown to be a potential target for Alzheimer’s disease therapies [84].